Tivic Health Systems Announces Research Study Approval
Tivic Health Systems, a leading health tech company, has recently shared exciting news about the approval of a research study at The Feinstein Institutes for Medical Research. This development has caused a significant surge in the company's shares, which rose by an impressive 48% to 10 cents.
After hitting a 52-week low of 4 cents earlier this week, Tivic Health Systems faced a challenging year with a 95% decline in its stock value over the past twelve months. However, with the approval of this study, there is new hope and optimism for the company.
The focus of this research study is Tivic Health Systems' innovative non-invasive bioelectronic device approach to vagus nerve stimulation. By targeting the vagus nerve through a unique neurostimulation method, the company aims to explore the potential benefits for various health conditions.
The pilot study will involve the participation of twenty individuals who will undergo the neurostimulation approach. Data analysis and algorithm development for this study will be carried out by renowned researchers at Feinstein Institutes' Institute of Bioelectronic Medicine.
This remarkable progress signifies a significant step forward for Tivic Health Systems and lays a foundation for potential breakthroughs in non-invasive bioelectronic therapies. With ongoing recruitment and enrollment for the study, the company is eager to gather valuable insights and explore the positive impact of their innovative approach.
All Rights Reserved © 2024
Post a comment